DaVita could be weak on Medicare Advantage rates, says Piper Jaffray Piper Jaffray believes shares of DaVita could be weak today following the release of Medicare's Advance Notice for 2015 Medicare Advantage rates, which it says was worse than expected. Piper notes Preliminary 2015 MA rates were down 7.8% versus expectations for a 6%-7% cut. The firm thinks final rates could improve and recommends buying shares of DaVita on any weakness. Piper maintains an Overweight rating on the stock with a $73 price target.
BofA/Merrill healthcare high yield analyst has analyst/industry conference call Healthcare High Yield Analyst Bland provides an update on the current state of the bond markets and the ability of healthcare providers to utilize debt financing on an Analyst/Industry conference call to be held on March 24 at 10 am.